|
SAV001-H is the first preventive HIV vaccine using a killed or "dead version" of HIV-1 virus. The vaccine is developed by Dr. Chil-Yong Kang and his research team at Western University’s Schulich School of Medicine & Dentistry in Canada. The result of the US FDA Phase I clinical trial completed in August 2013 showed no serious adverse effects in 33 participants. ==Vaccine Design== The SAV001-H vaccine is considered as the first genetically modified version of the killed whole HIV-1 vaccine. According to Dr. Kang, HIV-1 strain is genetically engineered such that first, “the gene responsible for pathogenicity, known as ''nef''” is removed to make it non-pathogenic and then the signal peptide gene is replaced with a honey bee toxin (melittin) signal peptide to make the virus production much higher and faster.〔Diagram of SAV001-H vaccine. ()〕 In the signal peptide exchange process, another gene called ''vpu'' is lost due to an overlapping. 〔Video Conference: HIV vaccine approved for human testing. ()〕 Finally, this genetically modified version of HIV-1, (i.e., HIV-1 virus with ''nef'' negative, ''vpu'' negative and signal peptide gene replaced with honey bee’s) grown in human T-lymphocytes (A3.01 cell line) are collected and purified before inactivating them by AT-2 (aldrithiol-2 or 2,2'-Dipyridyldisulfide) chemical treatment and gamma irradiation. AT-2 chemical treatment is used because it does not affect the viral structure and immunogens.〔Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. ()〕 This killed virus vaccine approach has successfully prevented polio, influenza, cholera, mumps, rabies, typhoid fever and hepatitis A for decades. At the moment, there are 16 animal vaccine based on this killed virus method including the feline immunodeficiency virus (which is closely related to HIV) vaccine for cats. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「SAV001」の詳細全文を読む スポンサード リンク
|